Literature DB >> 23268099

[Clinicopathological characteristics and treatment outcome of retroperitoneal liposarcoma].

Kenichi Chikatani1, Hiroyuki Baba, Jun Sobajima, Toru Ishiguro, Kensuke Kumamoto, Youichi Kumagai, Keiichiro Ishibashi, Norihiro Haga, Yoshitaka Tsuji, Takeo Iwama, Hideyuki Ishida.   

Abstract

Six patients with retroperitoneal liposarcoma were referred to our institution and retrospectively analyzed. Clinicopathological factors, initial treatment, postoperative recurrence, treatment, disease-free survival, and overall survival were investigated. Median age was 67 years and the male to female ratio was 0.5. Every patient underwent a surgical procedure as an initial treatment. Maximum tumor diameter was 190 mm (range, 100-250 mm). Three patients had local excisions, whereas the remaining 3 had extended surgery. Histological classification included well-differentiated type in 3, dedifferentiated type in 2, and mucinous type in 1. Three patients developed recurrence (local, n=3; hematogeneous, n=2). Local recurrence was excised but the disease relapsed in 2 patients. Median disease-free survival period was 21 months and 3-year survival rate was 62.5%. Since surgical resection remains the only promising treatment for liposarcoma, total removal of the tumor with negative surgical margins is mandatory. Wide resection, including the neighboring organs, should be performed without hesitation in selected cases.

Entities:  

Mesh:

Year:  2012        PMID: 23268099

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  A retrospective, single-center cohort study on 65 patients with primary retroperitoneal liposarcoma.

Authors:  Yi-Xi Wu; Jun-Yan Liu; Jia-Jia Liu; Peng Yan; Bo Tang; You-Hong Cui; Yong-Liang Zhao; Yan Shi; Ying-Xue Hao; Pei-Wu Yu; Feng Qian
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

2.  Prognostic factors predicting the postoperative survival period following treatment for primary retroperitoneal liposarcoma.

Authors:  Xudong Zhao; Peiyu Li; Xiaohui Huang; Lin Chen; Na Liu; Yaoguang She
Journal:  Chin Med J (Engl)       Date:  2015-01-05       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.